Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-122/Bryhali pediatric plaque psoriasis PK and HPA axis study
2024-520058-39-00Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of halobetasol in plaque psoriasis, sponsored by Valeant Pharmaceuticals. Primary endpoints: Safety of IDP-122 lotion administered topically once daily, Systemic exposure of halobetasol propionate after topical application and 1 more. Started Dec 2020; status: completed.
02
Drugs
halobetasol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-520058-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520058-39-00.